Total Payments
$193,104
2024 Payments
$11,744
Companies
39
Transactions
305
Medicare Patients
1,362
Medicare Billing
$250,418
Payment Breakdown by Category
Other$129,610 (67.1%)
Consulting$27,452 (14.2%)
Travel$26,221 (13.6%)
Food & Beverage$8,517 (4.4%)
Research$1,129 (0.6%)
Education$175.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $129,610 | 41 | 67.1% |
| Consulting Fee | $27,452 | 13 | 14.2% |
| Travel and Lodging | $26,221 | 68 | 13.6% |
| Food and Beverage | $8,517 | 175 | 4.4% |
| Unspecified | $1,129 | 3 | 0.6% |
| Education | $175.62 | 5 | 0.1% |
Payments by Type
General
$191,975
302 transactions
Research
$1,129
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $139,763 | 137 | $0 (2024) |
| Astellas Pharma US Inc | $27,079 | 32 | $0 (2023) |
| Incyte Corporation | $8,031 | 20 | $0 (2023) |
| F. Hoffmann-La Roche AG | $4,707 | 3 | $0 (2024) |
| PFIZER INC. | $3,559 | 4 | $0 (2023) |
| Gilead Sciences, Inc. | $3,402 | 3 | $0 (2018) |
| Stemline Therapeutics Inc. | $2,948 | 2 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $417.46 | 8 | $0 (2024) |
| Amgen Inc. | $382.75 | 14 | $0 (2022) |
| Celgene Corporation | $353.00 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,744 | 14 | JAZZ PHARMACEUTICALS INC. ($7,491) |
| 2023 | $40,654 | 67 | JAZZ PHARMACEUTICALS INC. ($33,949) |
| 2022 | $30,491 | 42 | JAZZ PHARMACEUTICALS INC. ($26,270) |
| 2021 | $21,959 | 33 | JAZZ PHARMACEUTICALS INC. ($17,279) |
| 2020 | $15,200 | 22 | Jazz Pharmaceuticals Inc. ($15,131) |
| 2019 | $49,835 | 65 | JAZZ PHARMACEUTICALS INC. ($24,957) |
| 2018 | $9,631 | 27 | Jazz Pharmaceuticals Inc. ($5,368) |
| 2017 | $13,590 | 35 | Jazz Pharmaceuticals Inc. ($9,318) |
All Payment Transactions
305 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,006.57 | Research |
| Study: A PHASE III RANDOMIZED OPEN LABEL ACTIVE CONTROLLED MULTICENTER STUDY EVALUATING EFFICACY AND SA | ||||||
| 03/18/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,580.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/18/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $33.38 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/18/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/18/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/18/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $17.42 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/13/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $201.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/09/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $347.52 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/08/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $81.54 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| 02/24/2024 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $1,187.53 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/24/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $63.01 | General |
| Category: Hematology | ||||||
| 02/24/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $49.93 | General |
| 02/23/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $94.02 | General |
| 12/29/2023 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,340.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $20.93 | General |
| 12/05/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $15.05 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2023 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $1,072.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/30/2023 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $122.03 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/14/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.10 | General |
| Category: Hematology | ||||||
| 11/02/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $96.75 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Oncology | ||||||
| 10/25/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.43 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III RANDOMIZED OPEN LABEL ACTIVE CONTROLLED MULTICENTER STUDY EVALUATING EFFICACY AND SA | F. Hoffmann-La Roche AG | $1,007 | 1 |
| A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T) | AbbVie Inc. | $61.23 | 1 |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | AbbVie Inc. | $61.23 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 331 | 909 | $211,658 | $66,039 |
| 2022 | 10 | 342 | 931 | $201,571 | $66,129 |
| 2021 | 11 | 350 | 1,024 | $181,751 | $67,514 |
| 2020 | 10 | 339 | 821 | $153,717 | $50,737 |
Total Patients
1,362
Total Services
3,685
Medicare Billing
$250,418
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 61 | 205 | $69,700 | $21,021 | 30.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 197 | $41,321 | $17,306 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 114 | 207 | $51,750 | $14,339 | 27.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 56 | $7,962 | $3,306 | 41.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 24 | $8,544 | $2,979 | 34.9% |
| 88187 | Flow cytometry technique for dna or cell analysis, 2 to 8 markers | Facility | 2023 | 54 | 102 | $15,708 | $2,542 | 16.2% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Facility | 2023 | 12 | 84 | $7,560 | $2,146 | 28.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 12 | 17 | $3,490 | $1,449 | 41.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 13 | 17 | $5,623 | $952.34 | 16.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 75 | 231 | $78,540 | $25,189 | 32.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 257 | $47,031 | $19,989 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 58 | 77 | $19,250 | $5,550 | 28.8% |
| 88187 | Flow cytometry technique for dna or cell analysis, 2 to 8 markers | Facility | 2022 | 65 | 144 | $22,176 | $3,714 | 16.7% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Facility | 2022 | 18 | 128 | $11,520 | $3,472 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $9,834 | $2,924 | 29.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $6,408 | $2,649 | 41.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 16 | $3,008 | $1,259 | 41.9% |
| 38206 | Collection of stem cells for transplantation | Facility | 2022 | 11 | 13 | $2,379 | $777.73 | 32.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 17 | 25 | $1,425 | $605.98 | 42.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 47 | 280 | $51,240 | $21,962 | 42.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 70 | 183 | $46,380 | $19,333 | 41.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 114 | $21,729 | $7,205 | 33.2% |
| 88346 | Antibody evaluation, initial single antibody stain procedure | Facility | 2021 | 17 | 187 | $16,830 | $5,188 | 30.8% |
| 88187 | Flow cytometry technique for dna or cell analysis, 2 to 8 markers | Facility | 2021 | 53 | 126 | $19,404 | $3,410 | 17.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 19 | $6,764 | $2,908 | 43.0% |
About Dr. John Edwards, MD
Dr. John Edwards, MD is a Hematology & Oncology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487692794.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Edwards, MD has received a total of $193,104 in payments from pharmaceutical and medical device companies, with $11,744 received in 2024. These payments were reported across 305 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($129,610).
As a Medicare-enrolled provider, Edwards has provided services to 1,362 Medicare beneficiaries, totaling 3,685 services with total Medicare billing of $250,418. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Indianapolis, IN
- Active Since 06/02/2006
- Last Updated 09/20/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487692794
Products in Payments
- VYXEOS (Drug) $130,421
- XOSPATA (Drug) $25,443
- Defitelio (Drug) $9,342
- ELREXFIO (Drug) $3,500
- Zydelig (Drug) $3,400
- ELZONRIS (Drug) $2,948
- JAKAFI (Drug) $464.85
- REBLOZYL (Biological) $371.81
- REZUROCK (Drug) $199.53
- VENCLEXTA (Drug) $189.74
- Epkinly (Drug) $181.55
- MONJUVI (Drug) $164.89
- Kyprolis (Drug) $158.22
- clonoSEQ (Device) $147.82
- UKONIQ (Drug) $125.00
- OJJAARA (Drug) $117.30
- CELLEX/XTS PHOTOPHERESIS SYSTEM (Device) $110.67
- Venclexta (Drug) $102.21
- SAMSCA (Drug) $102.13
- BRUKINSA (Drug) $90.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Indianapolis
Mr. Ruemu Birhiray, Md, MD
Hematology & Oncology — Payments: $3.3M
Hematology & Oncology $3.3M
Dr. Richard Gaynor, M.d, M.D
Hematology & Oncology — Payments: $3.2M
Hematology & Oncology $3.2M
Dr. Michael Dugan, M.d, M.D
Hematology & Oncology — Payments: $320,093
Hematology & Oncology $320,093
Anand Tandra, M.d, M.D
Hematology & Oncology — Payments: $257,904
Hematology & Oncology $257,904
Dr. Brandon Hardesty, M.d, M.D
Hematology & Oncology — Payments: $98,240
Hematology & Oncology $98,240
Kathy Miller, Md, MD
Hematology & Oncology — Payments: $79,815
Hematology & Oncology $79,815